Syros Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Syros Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Syros Pharmaceuticals Inc Strategy Report
- Understand Syros Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It offers services such as gene regulation, research and drug development, drug discovery, clinical trials among others. Syros is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
35 Cambridge Park Drive, Massachusetts, 02140
Website
syros.com
Telephone
1 617 7441340
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SYRS (NASD)
Revenue (2022)
$9.9M
-33.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-73.9%
(2022 vs 2021)
Market Cap*
$134.9M
Net Profit Margin (2022)
XYZ
-160.4%
(2022 vs 2021)
* As of and is in US$
Syros Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Gene Regulation |
| SY-2101 | Research and Drug Development |
| Acute Promyelocytic Leukemia | Drug Discovery |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Syros Pharmaceuticals Inc | Pfizer Inc | AbbVie Inc | Novartis AG | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | Cambridge | New York | North Chicago | Basel | Foster City |
| State/Province | Massachusetts | New York | Illinois | - | California |
| No. of Employees | 68 | 88,000 | 50,000 | 76,057 | 18,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Wirth | Chairman; Director | Executive Board | 2017 | 72 |
| Conley Chee | Chief Executive Officer; President | Senior Management | 2023 | - |
| Jason Haas | Chief Financial Officer | Senior Management | 2021 | 55 |
| Gerald E. Quirk | Chief Legal Officer; Compliance Officer | Senior Management | 2022 | 55 |
| David A. Roth | Chief Medical Officer | Senior Management | 2015 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer